

# Updates on the Diagnosis and Treatment of Insomnia

Charles M. Morin, PhD
Professor of Psychology
Canada Research Chair (Behavioral Sleep Medicine)
Quebec City, Canada
cmorin@psy.ulaval.ca



# Disclosures

| Nature of Relationship    | Organization   |  |  |
|---------------------------|--|--|--|
| Grant/Research Support    | Canadian Institutes of Health Research, National Institutes of Health, Fonds de Recherche en Santé du Québec, Novartis |  |  |
| Consultant/Advisory Board | Novartis, Merck, Valeant   |  |  |
| Speaker                   |  |  |  |
| Other                     | BeHealth Solutions   |  |  |
|                           |  |  |  |

# Learning Objectives

- Recognize clinical/diagnostic features of insomnia
- Identify approved medications for insomnia
- Learn cognitive-behavioral therapy principles
- Gain knowledge about benefits, risks, indications, and limitations of behavioral and pharmacological therapies for insomnia

# Key Messages

- Insomnia is characterized by sleep dissatisfaction, difficulties initiating or maintaining sleep, and significant impairments of daytime functioning
- Drug therapy produces rapid relief of symptoms, but there is limited evidence of long-term benefits; it is best indicated for short-term insomnia.
- CBT is the treatment of choice for chronic insomnia. Sleep improvements take more time than with medication, but they are well sustained over time.

# Diagnostic Criteria Insomnia Disorder

- Dissatisfaction with sleep quality or duration
- Subjective difficulties initiating/maintaining sleep
- Insomnia (or daytime consequences) causes marked distress or <u>significant impairment</u> in social or occupational functioning
- Sleep difficulties are present 3 nights or more per week and for more than 3 months


DSM5 no longer makes a distinction between primary and secondary insomnia

### Burden of Persistent Insomnia

- Psychiatric Increased risks of depression and suicide
- Health Reduced QoL and increased risks of hypertension
- Occupational Decreased job performance and increased absenteeism and risks of disability
- Economic Increased use of health care services/costs
- Public Safety Increased risks of accidents

Baglioni C et al. J Affect Disord 2011; 135:10-19; Laugsand et al. Circulation 2011; 124:2073-81. Daley M et al. Economic burden of insomnia. Sleep 2009; 32:55-64. Kyle S et al. Insomia and health-related quality of life. Sleep Med Rev 2010; 14:69-82. Sivertsen et al. The long-term effect of insomnia on work disability. Am J Epidemiol 2006 163:1018–1024

# The Natural History of Insomnia



# Treatment Options for Insomnia

- Pharmacotherapy
  - Benzodiazepine receptor agonists
  - Melatonin receptor agonists
  - Antidepressants
  - Antihistamines
- Cognitive Behavioral Therapy
- Complementary/alternative medicines (herbal, dietary supplements)

## Current State of Evidence on Insomnia Therapies

NIH State of the Science Conference (2005)
British Association for Psychopharmacology Consensus Statement (2009)

- Treatments endorsed for chronic insomnia:
  - Cognitive Behavioral Therapy
  - Benzodiazepine Receptor Agonists (at least for short-term use)
  - Melatonin-Receptor Agonists (especially for older adults)
- All other treatments <u>not endorsed</u> due to limited evidence of efficacy and/or safety concerns:
  - Complementary and alternative preparations
  - Antihistamines (OTC and prescription)
  - Antidepressants
  - Antipsychotics
- NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults (2005).
- British Association for Psychopharmacology Consensus Statement on Evidence-based Treatment of Insomnia, Parasomnias and Circadian Rhythm Disorders (2009).

# What is Cognitive Behavioral Therapy (CBT)?

- CBT is a psychotherapeutic method aimed at changing behaviors (sleep schedules/habits) and cognitions (sleep worries, beliefs) that perpetuate insomnia
- CBT is brief (4-6 consultation visits), directive, and sleep-focused; it involves education and prescription for behavior changes
- CBT is based on a collaborative patient-therapist relationship (problem-solving focus)

# Cognitive Behavioral Therapy

(Treatment Targets)

#### Behavioral

Sleep Restriction
Stimulus Control
Relaxation

Excessive time in bed
Irregular sleep schedules
Sleep incompatible activities
Hyperarousal

#### **Cognitive**

Cognitive Therapy Paradoxical Intention

Unrealistic sleep expectations
Misconceptions about sleep
Sleep-related worries
Poor coping skills

#### **Educational**

Sleep Hygiene Education Sleep Information

Inadequate sleep hygiene (caffeine, alcohol, exercise, environmental factors)

## Behavioral/Sleep Scheduling Prescriptions

- Restrict time in bed to actual sleep time
- Go to bed only when sleepy
- Use the bed/bedroom for sleep only
- Get out of bed when unable to sleep
- Get up at the same time every morning
- Do not nap during the day

#### Objectives:

- 1) Reinforce the association between sleep and bedroom stimuli
- 2) Establish a regular sleep-wake rhythm and strenghten the homeostatic drive

# Sleep Restriction

- Restrict time in bed (TIB) to actual sleep time
- Alter TIB based upon SE (by block of 15-20 min)
- Increase TIB if SE >90%; decrease TIB if SE <80%
- Modify the sleep window until optimal sleep duration is achieved
- Caution: do not use with patients presenting daytime sleepiness, seizures, bipolar disorder

## Cognitive Therapy Principles for Insomnia

- <u>Identify</u> faulty beliefs and attitudes about sleep and excessive worries about insomnia and its consequences
  - Unrealistic expectations (I must get 8 hours of slep)
  - Etiologic misconceptions (Insomnia is due to chemical imbalance)
  - Amplification of consequences (Unable to function if less than 8 hours sleep; insomnia may be detrimental to health)
  - Sleep promoting behaviors (Should stay in bed if can't sleep)
- <u>Challenge</u> validity of those beliefs with socratic dialogue and behavioral experiments
- Replace with more adaptive substitutes/perceptions

## Summary of Outcome Evidence

#### Benefits

- 80% of patients benefit from CBT
- 50%-60% symptom reductions (SOL, WASO)
- 40% remission and 60% response rates (ISI)
- Sleep changes well sustained over time

#### Indications


- Persistent insomnia, both primary and comorbid
- Younger and older adults
- Singly or as augmentation therapy to hypnotics

Morin et al. Cognitive-behavioral therapy, singly and combined with medication, for persistent insomnia. JAMA 2009; 301: 2005-15.

Morin CM, Benca R. Chronic insomnia. The Lancet 2012; 379;1129-1141

# Pharmacological Treatments

- Benzodiazepines/BzRAs
- Sedating antidepressants
- Antihistamines
- Melatonin receptor agonists
- Orexin receptor antagonists



#### Medications Indicated for the Treatment of Insomnia

| <b>Medication Class</b> | Agent          | T <sub>1/2</sub> (Hour) | Dose (mg)  |  |
|-------------------------|----------------|-------------------------|------------|--|
| Benzodiazepines         | Flurazepam     | 48-120                  | 15-30      |  |
|                         | Temazepam      | 8-20                    | 15-30      |  |
|                         | Triazolam      | 2-6                     | 0.125-0.25 |  |
|                         | Estazolam      | 8-24                    | 1-2        |  |
|                         | Quazepam       | 48-120                  | 7.5-15     |  |
| Non-BZD                 | Zolpidem IR MR | 1.5-2.4                 | 5-12.5     |  |
|                         | Zaleplon       | 1                       | 5-20       |  |
|                         | Eszopiclone    | 5-7                     | 1-3        |  |
| Melatonin Agonist       | Ramelteon      | 1.5-5                   | 8          |  |
| Orexin Antagonist       | Suvorexant     | 0.5-6                   | 12-13      |  |
| Antidepressant          | Doxepin        | 1.5-4                   | 3-6        |  |

## Medications Used Off-Label for Insomnia

| <b>Medication Class</b> | Agent         | T <sub>1/2</sub> (h) | Dosage (mg) |
|-------------------------|---------------|----------------------|-------------|
| Benzodiazepines         | Alprazolam    | 12-24                | 0.25-2      |
|                         | Clonazepam    | 35-40                | 0.25-2      |
|                         | Lorazepam     | 12-15                | 0.5-2       |
| Antidepressants         | Amitriptyline | 20-30                | 10-75       |
|                         | Mirtazapine   | 20-40                | 15-45       |
|                         | Trazodone     | 5-9                  | 50-150      |
| Antipsychotics          | Olanzapine    | 21-54                | 5-10        |
|                         | Quetiapine    | 6                    | 25-200      |
|                         | Risperidone   | 3-20                 | 1-8         |
| Anticonvulsants         | Gabapentin    | 5-7                  | 300-600     |
|                         | Pregabalin    | 1                    | 150-300     |

# Effects of Benzodiazepine-Receptor Agonists on Sleep

- Sleep Continuity
  - Shorten SOL and WASO
  - Decrease number of awakening and stage shifts
  - Increase total sleep time
- Sleep Architecture
  - Decrease Stage 1 and increase Stage 2
  - Decrease Stages 3-4, REM Sleep
- Improve Subjective Sleep Quality


Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmaceutical treatments for insomnia: The empirical basis for U.S. clinical practice. Sleep Med Rev 2009; 13 265-74.

### Risks/Limitations of BzRAs

- Next day residual sedation
- Cognitive and psychomotor impairments
- Tolerance
- Dependence (psychological)
- Rebound insomnia

These effects vary as a function of several factors: dose, half-life, duration of use, age and gender, and some psychological factors

# Efficacy of Behavioral and Pharmacological Therapies



Morin et al., 1994; Murtagh & Greenwood, 1995; Nowell et al., 1997; Smith et al., 2002


# Benefits and Limitations of CBT and Medication for Insomnia

- Cognitive Behavioral Therapy
  - Efficacious, sustained improvements over time
  - Well accepted, few adverse effects
  - Requires time and motivation
  - Compliance may be a problem
- Medication
  - Efficacious, rapid symptomatic relief
  - Limited evidence of long-term efficacy
  - Potential risks for side effects
  - Concerns about dependency

No single treatment is effective or acceptable for all patients with insomnia

## CBT, Medication, and Combined Therapies

(N = 76, mean age 66 y/o)



Morin et al. JAMA 1999; 281:991-999.

# Combined/Sequential Therapies

- Potential advantages
  - Combines the rapid action of medication and the durability of CBT
  - Takes into account patient's preferences and potential impact of different insomnia phenotypes
- Disadvantages
  - Risk for attribution of sleep improvements to medication alone
  - May undermine compliance with CBT and the development of beneficial self-management skills
  - Risk of dependency on medication

## What are the Essential Components?

- Sleep diary monitoring
- Behavioral/sleep scheduling strategies
  - Restriction of time spent in bed
  - Postponing bedtime until sleep is imminent
  - Regular arising time regardless of sleep duration
  - Getting out of bed when not sleeping
- Education/information about sleep/insomnia
  - Appropriate age-related sleep expectations
  - Sleep-related worries
  - Misconceptions about sleep and insomnia

## Key Points/Conclusions

- Insomnia is a prevalent clinical complaint that often presents with other medical and psychiatric disorders
- Persistent insomnia carries significant long-term morbidity
- Approved medications for insomnia provide rapid symptomatic improvements, but there is limited evidence of sustained benefits after drug discontinuation or sustained benefits with prolonged use
- CBT is efficacious, produces sustained benefits, and is well accepted by patients